Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 10/20 | 0.55 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.55 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.55 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.55 |
| ▸ | RAF1 | P04049 | 1/20 | 0.55 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.55 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | GCGR | P47871 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.37 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8815350 | 0.83 | NR3C2 (0.40) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL10989579 | 0.82 | KDM5B (0.40) | MAPK14CYP3A4KDM4EMAPTPDPK1 | |
| SCHEMBL7089424 | 0.78 | MAPK14 (0.46) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL10992179 | 0.75 | MAPK14 (0.83) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL10892833 | 0.74 | KDM4E (0.56) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL7090773 | 0.74 | BRAF (0.48) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| Hydrochloric Acid SCHEMBL30023185 | 0.73 | MAPK14 (0.80) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL7833395 | 0.73 | PTGS2 (0.52) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL7085451 | 0.73 | MAPK14 (0.42) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL7089149 | 0.73 | MAPK14 (0.47) | MAPK14MAPK13MAPK12MAPK11MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030050330-A1 | 4,5-subtstituted imdazolyl compounds for the treatment of inflammation | G.D. SEARLE & CO. | 2003-03-13 | — | — | US | disclosed |
| EP-0772601-B1 | 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2002-09-18 | — | — | EP | disclosed |
| US-6426360-B1 | ANTIARTHRITIC AGENTS | G D SEARLE & CO. | 2002-07-30 | — | — | US | disclosed |
| EP-1211244-A2 | 4,5-substitued imidazolyl compounds for the treatment of inflammation | G.D. Searle & Co. (US) | 2002-06-05 | — | — | EP | disclosed |
| US-5620999-A | ANTIARTHRITIC, ANALGESIC AND ANTIPYRATIC AGENT | G.D. SEARLE & CO. | 1997-04-15 | — | — | US | disclosed |
| WO-1996003387-A1 | 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050330-A1 | 4,5-subtstituted imdazolyl compounds for the treatment of inflammation | AHR, HACL2, IRAK2 | MAPK14 1523/4885MAPK13 2251/4885MAPK12 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.